1. Home
  2. VPG vs DRUG Comparison

VPG vs DRUG Comparison

Compare VPG & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VPG
  • DRUG
  • Stock Information
  • Founded
  • VPG 2009
  • DRUG 2019
  • Country
  • VPG United States
  • DRUG United States
  • Employees
  • VPG N/A
  • DRUG N/A
  • Industry
  • VPG Electrical Products
  • DRUG Pharmaceuticals and Biotechnology
  • Sector
  • VPG Technology
  • DRUG Health Care
  • Exchange
  • VPG Nasdaq
  • DRUG Nasdaq
  • Market Cap
  • VPG 293.3M
  • DRUG 253.2M
  • IPO Year
  • VPG N/A
  • DRUG N/A
  • Fundamental
  • Price
  • VPG $23.95
  • DRUG $37.78
  • Analyst Decision
  • VPG Hold
  • DRUG Strong Buy
  • Analyst Count
  • VPG 1
  • DRUG 4
  • Target Price
  • VPG $31.00
  • DRUG $84.33
  • AVG Volume (30 Days)
  • VPG 85.8K
  • DRUG 39.1K
  • Earning Date
  • VPG 05-06-2025
  • DRUG 05-16-2025
  • Dividend Yield
  • VPG N/A
  • DRUG N/A
  • EPS Growth
  • VPG N/A
  • DRUG N/A
  • EPS
  • VPG 0.74
  • DRUG N/A
  • Revenue
  • VPG $306,522,000.00
  • DRUG N/A
  • Revenue This Year
  • VPG $2.60
  • DRUG N/A
  • Revenue Next Year
  • VPG $6.04
  • DRUG N/A
  • P/E Ratio
  • VPG $32.54
  • DRUG N/A
  • Revenue Growth
  • VPG N/A
  • DRUG N/A
  • 52 Week Low
  • VPG $20.83
  • DRUG $0.93
  • 52 Week High
  • VPG $35.52
  • DRUG $79.02
  • Technical
  • Relative Strength Index (RSI)
  • VPG 57.20
  • DRUG 48.17
  • Support Level
  • VPG $22.91
  • DRUG $35.35
  • Resistance Level
  • VPG $25.15
  • DRUG $37.90
  • Average True Range (ATR)
  • VPG 0.79
  • DRUG 2.06
  • MACD
  • VPG 0.26
  • DRUG 0.18
  • Stochastic Oscillator
  • VPG 70.44
  • DRUG 52.85

About VPG Vishay Precision Group Inc.

Vishay Precision Group Inc manufactures and markets sensors, and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: